We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Osiris seals billion-dollar deal with Genzyme for cell therapy.
- Authors
Mack, George S.
- Abstract
The article discusses business dealings between Genzyme of Cambridge, MA and Osiris Technologies of Columbia, MD regarding mesenchymal stem cell (MSC) technology. Genzyme purchased rights from Osiris to sell its MSC treatments in all countries except for the United States and Canada. Drugs that are close to U.S. Food and Drug Administration (FDA) approval and commercialization are Prochymal and Chondrogen. Treatments are discussed for graft-versus-host disease, Crohn's disease, knee cartilage regeneration, acute radiation sickness, osteoarthritis, cardiovascular disease, diabetes, and chronic obstructive pulmonary disease (COPD). Also discussed are a contract with the U.S. Department of Defense, MSC drug manufacture, and clinical trail results.
- Subjects
UNITED States; GENZYME Corp.; OSIRIS BV; PHARMACEUTICAL biotechnology; STEM cells; ACQUISITION of property; MERGERS &; acquisitions; UNITED States. Food &; Drug Administration; UNITED States. Dept. of Defense; INFLAMMATORY bowel disease treatment; RADIATION injuries; DIABETES
- Publication
Nature Biotechnology, 2009, Vol 27, Issue 2, p106
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0209-106